Pulido, FedericoRibera, EstebanLagarde, MariaPerez-Valero, IgnacioPalacios, RosarioIribarren, Jose A.Payeras, AntoniDomingo, PereSanz, JoseCervero, MiguelCurran, AdrianRodriguez-Gomez, Francisco J.Tellez, Maria J.Ryan, PabloBarrufet, PilarKnobel, HernandoRivero, AntonioAlejos, BelenYllescas, MariaArribas, Jose R.DUAL-GESIDA-8014-RIS-EST45 Study G2023-02-122023-02-122017-12-151058-4838http://hdl.handle.net/10668/18942Background. Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression.Methods. This was a multicenter, open-label, noninferiority trial (margin 12%). Patients with HIV-1 RNAendarunavir/ritonavirlamivudineswitchdual therapyNon-inferiority trialReverse-transcriptase inhibitorVirologically stable patientsBoosted protease inhibitorAntiretroviral therapyCoformulated elvitegravir2 nucleos(t)idesPhase 3bSimplificationHivAdultAdultAnti-HIV AgentsCD4 Lymphocyte CountDarunavirDideoxynucleosidesEmtricitabineFemaleHIV InfectionsHIV Protease InhibitorsHIV-1HumansLamivudineMaleMedication Therapy ManagementMiddle AgedRNA, ViralRitonavirTenofovirViral LoadDual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trialresearch articleopen access10.1093/cid/cix7341537-6591https://academic.oup.com/cid/article-pdf/65/12/2112/21968140/cix734.pdf416494500022